Simbec-Orion

If you are considering placing your phase I study in the UK, you may have come across CROs or Phase I Units with an MHRA Phase I accreditation – but what does this mean? Find out in our latest blog post

Thanks to more awareness and better diagnostic tools, individuals living with ADHD are more likely to be diagnosed early and if necessary, receive medication to help reduce symptoms, focus their thoughts and better ignore distractions. While such treatments may not be appropriate in all cases, we support our colleagues in research as they drive toward better treatments for all.

Will you be meeting investors at #BIOEurope in Stockholm next month? To better support early-phase planning, we have partnered with biotx.ai GmbH, and together we can empower our clients with access to causal AI modeling. This platform mimics prospective, randomised clinical trials by utilising the genomes, full phenotypes, and medical histories of 3.3 million patients to predict clinical trial outcomes. The data, combined with our guidance on study design and strategy, can help our clients demonstrate the value of their compound in a challenging investment market and de-risk their clinical development. Connect with us now to set up your CDA before you get there https://bit.ly/3XRG5rp

We worked with our colleagues at CUBRIC and The Science Behind to design and deliver a 3-part First-in-Human study in a potential treatment for schizophrenia, developed by Cardiff University's Medicines Discovery Institute. Read the full case study to learn how we navigated the unique logistical challenges of this 4-way collaboration https://bit.ly/3N5eZXn 

OCT Nordics 2024 is in full swing and Qaisar Rafiq and Jonny Quinn are on hand to speak with you about your clinical trial needs. Our full capability encompasses everything from FiH in volunteers or patients right through to Phase III. Make sure you connect with them #clinicaltrials #phaseI #phaseII #phaseIII

Our colleagues Qaisar Rafiq and Jonny Quinn are attending OCT Nordics 2024 in Copenhagen. Look out for them over the next two days! #clinicaltrial #firstinhuman #phaseI #phaseII #phaseIII

In 2022, female breast cancer was the second most common cancer worldwide, there were 2.3 million women diagnosed with breast cancer and 660,000 deaths as a result of breast cancer.* The global 5-year survival rate exceeds 90% in high-income countries, compared to 66% in India and 40% in South Africa. The goal of the WHO Global Breast Cancer Initiative is to reduce the incidence of breast cancer by 2.5% per year, aiming to save 2.5 million lives over 20 years.** * Bray F, Laversanne M, Sung H, Ferlay J, Siegal RL, Soerjomataram I, et al Global Cancer Statistics 2022 Accessed 29 Sep 2024 ** WHO The Global Breast Cancer Initiative. Accessed 29 Sep 2024

Our colleagues, Qaisar Rafiq and Jonny Quinn are travelling to Copenhagen today to attend OCT Nordics 2024. If you would like to find out how we can support your clinical development journey, even before you've submitted your trial application, make sure you speak to them at the meeting! #clinicaltrial #firstinhuman #phaseI #phaseII #phaseIII

Our colleague Romillie Cruz, MD will be attending the Cambridge Rare Disease Showcase again next week but this time, as part of the patients and carers community. Having experience in caring for a patient living with a rare disease, as well as working in the clinical research industry, Romillie understands the importance of partnering closely with patient advocacy groups throughout the clinical trial process and always strives to amplify patients' voices during protocol development. We are truly grateful to have her on our team.

AI-enabled causal modelling can support your decisions from preclinical into FiH studies. From uncovering data that supports efficacy to predicting outcomes in Phase II, it can provide the tools you need to secure further investment. Learn more https://lnkd.in/ePF88vyj